Technology
Share your love
Porter Ophthalmology Clarifies Long-Term Vision Planning for LASIK Patients Considering Cataract Surgery
Raleigh, NC – October 27, 2025 – PRESSADVANTAGE – With millions of Americans having undergone LASIK vision correction in the past three decades, a growing number are now approaching the age where cataract surgery becomes a consideration. Porter Ophthalmology, a…
Q&A: William F. Wiley, MD, on what BVI’s trifocal IOL approval means for US premium vision options | Ophthalmology Times
The FDA’s approval of the FineVision HP trifocal lens expands the range of premium lens option to US ophthalmologists and their patients. (Image credit: AdobeStock/Margarita Ratatosk) As the landscape of ophthalmic innovation continues to evolve, new technologies are reshaping how…
Precision strategy: Optimizing visual outcomes with advanced small-aperture lenses | Ophthalmology Times
(Image Credit: AdobeStock/Wirestock) A recent Ophthalmology Times Case-Based Roundtable addressed the pathway to achieving optimized visual outcomes using an advanced small-aperture IOL (IC-8 Apthera; Bausch + Lomb Surgical). Mark Lobanoff, MD, an ophthalmologist in St Louis Park, Minnesota, shared the highlights…
Evolving glaucoma therapy: A new era of interventional strategies | Ophthalmology Times
(Image Credit: AdobeStock/Yakobchuk Olena) Inder Paul Singh, MD, from The Eye Centers of Racine and Kenosha, Wisconsin, recently moderated an Ophthalmology Times Case-Based Roundtable that addressed the new playing field in glaucoma care. For Singh, the term interventional glaucoma no…
Throwback Series: When tools of the past teach new lessons | Ophthalmology Times
In celebration of Ophthalmology Times’ 50th anniversary, leaders revisit a memorable “throwback” case from earlier in their careers. In this special series, they reflect on how evolving knowledge, techniques, and technologies have transformed the way such cases are managed today.…
Periorbital rejuvenation: Past, present, and next | Ophthalmology Times
(Image Credit: AdobeStock/Alessandro Grandini) The aesthetic treatment of the periorbital region has evolved significantly, shaped by centuries of innovation and driven by the desire to understand anatomy and how it is affected by aging. Among the earliest documented advancements in…
AAO 2025: Margaret A. Chang, MD, MS, highlights OTX-TKI’s impact on retinal fluid | Ophthalmology Times
Margaret A. Chang, MD, MS, presented updates from the HELIOS Phase 1 trial of OTX-TKI, a sustained-release formulation of the tyrosine kinase inhibitor, axitinib, for the treatment of diabetic retinopathy (DR), at the American Academy of Ophthalmology 2025 annual meeting,…
Starting from scratch on neovascular age-related macular degeneration | Ophthalmology Times
(Image Credit: AdobeStock) Luis Arias, MD; and Paolo Lanzetta, MD, recently found themselves on opposite sides of the debate table regarding the value of gene therapy to treat neovascular age-related macular degeneration (nAMD) at the 16th Annual Congress on Controversies…
Breaking down the barriers: Ophthalmic care in the incarcerated population | Ophthalmology Times
(Image Credit: AdobeStock/methaphum) The US has the highest incarcerated population globally, with Black, Indigenous, or Hispanic individuals significantly more likely to be imprisoned than White individuals. These racial disparities mirror those seen in vision health and access to eye care.1,2…
Charles Miller, MD, PhD, on DME research and the initiation of the phase 2b/3 BRUNELLO trial | Ophthalmology Times
Image credit: AdobeStock/MrAshi On September 4, 2025, Merck and EyeBio announced that the companies have initiated the Phase 2b/3 BRUNELLO trial (NCT06571045) to evaluate the candidate MK-3000, formerly known as EYE103 for the treatment of patients with diabetic macular edema…